Mark G Kris

Mark G Kris

UNVERIFIED PROFILE

Are you Mark G Kris?   Register this Author

Register author
Mark G Kris

Mark G Kris

Publications by authors named "Mark G Kris"

Are you Mark G Kris?   Register this Author

100Publications

3738Reads

48Profile Views

Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.

J Thorac Oncol 2019 Oct 19;14(10):1784-1793. Epub 2019 Jun 19.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.06.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764905PMC
October 2019

Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.

Clin Lung Cancer 2019 Oct 13. Epub 2019 Oct 13.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.10.002DOI Listing
October 2019

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.

J Thorac Oncol 2019 Sep 20;14(9):1666-1671. Epub 2019 Jun 20.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.06.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708730PMC
September 2019

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.

J Thorac Oncol 2019 May 1;14(5):802-815. Epub 2019 Mar 1.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486868PMC
May 2019

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with -Mutant Lung Cancers.

Clin Cancer Res 2019 02 25;25(3):1063-1069. Epub 2018 Jul 25.

Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347551PMC
February 2019

Inflamed Actinic Keratoses After Pemetrexed.

Skinmed 2016;14(6):473-474. Epub 2016 Dec 1.

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
September 2018

Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.

Cancer Immunol Res 2018 09 10;6(9):1093-1099. Epub 2018 Jul 10.

Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-17-0755DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125223PMC
September 2018

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.

J Clin Oncol 2018 08 15;36(23):2386-2394. Epub 2018 Jun 15.

M. Catherine Pietanza, Lee M. Krug, Mark G. Kris, and Charles M. Rudin, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College; Kaitlin M. Woo, Yevgeniva Bensman, Brenda Hurtado, and Martin Fleisher, Memorial Sloan Kettering Cancer Center, New York, NY; Saiama N. Waqar, Washington University School of Medicine in St. Louis, St Louis, MO; Afshin Dowlati, Case Western Reserve University and University Hospitals Seidman Cancer Center, Cleveland, OH; Christine L. Hann, Johns Hopkins University, Baltimore; Alice Chen, National Institutes of Health, Bethesda, MD; Alberto Chiappori, H. Lee Moffitt Cancer Center, Tampa, FL; Taofeek K. Owonikoko, Emory University, Atlanta, GA; and Robert J. Cardnell, Junya Fujimoto, Lihong Long, Lixia Diao, Jing Wang, Patricia de Groot, Erik P. Sulman, Ignacio I. Wistuba, John V. Heymach, and Lauren Averett Byers, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.77.7672DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085179PMC
August 2018

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

J Clin Oncol 2018 08 10;36(24):2532-2537. Epub 2018 Jul 10.

Bob T. Li, Ronglai Shen, Darren Buonocore, Zachary T. Olah, Ai Ni, Michelle S. Ginsberg, Gary A. Ulaner, Michael Offin, Daniel Feldman, Helen H. Won, Edyta B. Brzostowski, Gregory J. Riely, David B. Solit, David M. Hyman, Alexander Drilon, Charles M. Rudin, Michael F. Berger, Jose Baselga, Maurizio Scaltriti, Maria E. Arcila, and Mark G. Kris, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY; Bob T. Li, Nick Pavlakis, and Stephen Clarke, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; and Todd Hembrough, Fabiola Cecchi, and Sarit Schwartz, NantOmics, Rockville, MD.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.77.9777
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.77.9777DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366814PMC
August 2018

Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.

Lung Cancer 2018 08 22;122:67-71. Epub 2018 May 22.

Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.05.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062851PMC
August 2018

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

J Clin Oncol 2018 03 16;36(7):633-641. Epub 2018 Jan 16.

Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson, Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub, Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A. Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.3384DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075848PMC
March 2018

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

J Oncol Pract 2017 12 24;13(12):825-830. Epub 2017 Aug 24.

Lahey Hospital and Medical Center, Burlington, MA; American Society of Clinical Oncology, Alexandria, VA; and Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2017.026351DOI Listing
December 2017

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.

Cancer 2017 Nov 25;123(21):4099-4105. Epub 2017 Jul 25.

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30869DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650517PMC
November 2017

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.

J Clin Oncol 2017 Oct 31;35(28):3240-3261. Epub 2017 Jul 31.

Paul J. Hesketh, Lahey Hospital and Medical Center, Burlington; Kimberly Noonan, Dana-Farber Cancer Institute, Boston, MA; Mark G. Kris, Memorial Sloan Kettering Cancer Center, New York, NY; Ethan Basch and Stacie B. Dusetzina, University of North Carolina at Chapel Hill, Chapel Hill; Sally Y. Barbour, Duke University Medical Center, Durham, NC; Kari Bohlke and Mark R. Somerfield, American Society of Clinical Oncology, Alexandria; Michael A. Danso, Virginia Oncology Associates, Virginia Beach; Michael A. Danso, Virginia Oncology Associates, Norfolk, VA; Rebecca Anne Clark-Snow, University of Kansas Cancer Center, Westwood, KS; Cathy Eng, The University of Texas MD Anderson Cancer Center, Houston, TX; Dee Sparacio, Patient Representative, Hightstown, NJ; Gary H. Lyman, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Kristopher Dennis, The Ottawa Hospital and University of Ottawa, Ottawa; L. Lee Dupuis, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada; Petra C. Feyer, Vivantes Clinics Neukoelln, Berlin; and Karin Jordan, University of Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.4789DOI Listing
October 2017

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.

J Clin Oncol 2017 Sep 24;35(25):2960-2974. Epub 2017 Apr 24.

Mark G. Kris and Jamie E. Chaft, Memorial Sloan Kettering Cancer Center; Harvey I. Pass, New York University Langone Medical Center, New York; Rahul Seth, Upstate Medical Center, Syracuse University, Syracuse, NY; Laurie E. Gaspar and Michael Weyant, University of Colorado School of Medicine, Aurora, CO; Erin B. Kennedy, American Society of Clinical Oncology, Alexandria, VA; Christopher G. Azzoli, Massachusetts General Hospital, Boston, MA; Steven H. Lin, MD Anderson Cancer Center; John R. Strawn, Patient Representative, Houston, TX; David R. Spigel, Sarah Cannon Cancer Center, Nashville, TN; Peter M. Ellis, Juravinski Cancer Center, Hamilton Health Sciences, Hamilton; Frances A. Shepherd, Princess Margaret Cancer Centre, University Health Network; and Yee C. Ung, Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.4401DOI Listing
September 2017

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stages I to IIIA Resectable Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update Summary.

J Oncol Pract 2017 07 25;13(7):449-451. Epub 2017 Apr 25.

University of Colorado School of Medicine, Anschutz, CO; Memorial Sloan Kettering Cancer Center, New York City, NY; and American Society of Clinical Oncology, Alexandria, VA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2017.022251DOI Listing
July 2017

Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.

Nat Commun 2017 07 17;8:16078. Epub 2017 Jul 17.

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms16078DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520052PMC
July 2017

Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas.

Lung Cancer 2017 06 28;108:205-211. Epub 2017 Mar 28.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 E 66(th) St., New York, NY 10065, USA; Department of Medicine, Weill Cornell Medical College, 1300 York Ave., New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.03.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423973PMC
June 2017

A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib.

J Thorac Oncol 2017 01 6;12(1):102-109. Epub 2016 Sep 6.

Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.08.140DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552054PMC
January 2017

KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.

Am J Surg Pathol 2016 12;40(12):1579-1590

*Department of Surgery, Thoracic Service †Department of Pathology §Department of Epidemiology and Biostatistics ∥Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology ¶Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY ‡Department of Diagnostic Pathology, Faculty of Medicine, Kagawa University, Kagawa, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000744DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106330PMC
December 2016

The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.

Lung Cancer 2016 12 17;102:21-27. Epub 2016 Oct 17.

Sydney Medical School, University of Sydney, Sydney, NSW 2006, Australia; Department of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW 2065, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.10.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441998PMC
December 2016

Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.

Clin Lung Cancer 2016 09 21;17(5):e121-e129. Epub 2016 Jan 21.

Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.01.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474315PMC
September 2016

Reply to J. Jupp et al.

J Clin Oncol 2016 09 18;34(27):3353. Epub 2016 Jul 18.

Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.6147DOI Listing
September 2016

Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.

Lung Cancer 2016 09 31;99:53-6. Epub 2016 May 31.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, NY, USA; Sydney Medical School, University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.05.030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5305295PMC
September 2016

Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial.

Clin Trials 2016 06 4;13(3):331-7. Epub 2015 Nov 4.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1740774515615540DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228492PMC
June 2016

Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas.

J Thorac Oncol 2016 06 8;11(6):890-9. Epub 2016 Mar 8.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.02.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877255PMC
June 2016

Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial.

J Thorac Oncol 2016 Apr 25;11(4):537-44. Epub 2015 Dec 25.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2015.12.104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808609PMC
April 2016

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.

J Thorac Oncol 2016 Mar 24;11(3):414-9. Epub 2015 Dec 24.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Molecular Diagnostics Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2015.10.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4698879PMC
March 2016

Antiemetics: American Society of Clinical Oncology Focused Guideline Update.

J Clin Oncol 2016 Feb 2;34(4):381-6. Epub 2015 Nov 2.

Paul J. Hesketh, Lahey Hospital and Medical Center, Burlington, MA; Kari Bohlke and Mark R. Somerfield, American Society of Clinical Oncology, Alexandria; Michael A. Danso, Virginia Oncology Associates, Norfolk and Virginia Beach, VA; Gary H. Lyman, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Ethan Basch, University of North Carolina at Chapel Hill, Chapel Hill, NC; Maurice Chesney, patient representative, Saunderstown, RI; Rebecca Anne Clark-Snow, University of Kansas Cancer Center, Westwood, KS; Karin Jordan, University Hospital, Martin-Luther-University Halle-Wittenberg, Halle, Germany; and Mark G. Kris, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.64.3635
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.64.3635DOI Listing
February 2016

Medians and Milestones in Describing the Path to Cancer Cures: Telling "Tails".

JAMA Oncol 2016 Feb;2(2):167-8

Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York2Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.4345DOI Listing
February 2016

Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

J Clin Oncol 2016 Feb 7;34(6):557-65. Epub 2015 Dec 7.

Ethan Basch, Mark G. Kris, Howard I. Scher, Clifford A. Hudis, Paul Sabbatini, Lauren Rogak, Thomas M. Atkinson, Joanne F. Chou, Dorothy Dulko, Laura Sit, Michael Fruscione, and Deborah Schrag, Memorial Sloan Kettering Cancer Center, New York, NY; Ethan Basch, Allison M. Deal, and Antonia V. Bennett, University of North Carolina, Chapel Hill, NC; Amylou C. Dueck, Mayo Clinic, Scottsdale, AZ; Allison Barz, Children's Hospital of Philadelphia, Philadelphia, PA; Paul Novotny and Jeff A. Sloan, Mayo Clinic, Rochester, MN; and Deborah Schrag, Dana-Farber/Harvard Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.0830DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872028PMC
February 2016

Antiemetics: American Society of Clinical Oncology Focused Guideline Update.

J Oncol Pract 2016 Jan;12(1):88-89

Lahey Hospital and Medical Center, Burlington, MA; American Society of Clinical Oncology, Alexandria, VA; and Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2015.009282DOI Listing
January 2016

Chemotherapy for lung cancers: here to stay.

Am Soc Clin Oncol Educ Book 2014 :e375-80

From the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2014.34.e375DOI Listing
December 2015

Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.

J Thorac Oncol 2015 Dec;10(12):1713-9

*Thoracic Oncology Service, Department of Medicine, †Department of Epidemiology and Biostatistics, ‡Department of Radiology, and §Department of Pathology, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153509
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000671DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760768PMC
December 2015

HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.

Lung Cancer 2015 Dec 29;90(3):617-9. Epub 2015 Oct 29.

Sydney Medical School, University of Sydney, Sydney, Australia; Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.10.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724317PMC
December 2015

EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.

Cancer Discov 2015 Nov 18;5(11):1155-63. Epub 2015 Aug 18.

Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee. Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-15-0654DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631701PMC
November 2015

Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.

Cancer 2015 Jun 17;121(12):2078-82. Epub 2015 Mar 17.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29313DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783794PMC
June 2015

Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases.

Cancer Discov 2015 Jun 30;5(6):610-21. Epub 2015 Apr 30.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-1129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643059PMC
June 2015

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

J Clin Oncol 2015 May 13;33(15):1666-73. Epub 2015 Apr 13.

Melissa L. Johnson, Jyoti D. Patel, Eric M. Hart, Bing Bing Weitner, and Alfred W. Rademaker, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; and Helena A. Yu, Mark G. Kris, and Gregory J. Riely, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/04/13/JCO.2014.59
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.59.7328
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.7328DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881377PMC
May 2015

Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer.

Cancer Biomark 2014 ;14(4):207-14

Department of Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-140399DOI Listing
April 2015

MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.

Clin Cancer Res 2015 Apr 28;21(8):1935-43. Epub 2014 Oct 28.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2124DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401580PMC
April 2015

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.

J Thorac Oncol 2015 Mar;10(3):431-7

*Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, †Department of Epidemiology and Biostatistics, ‡Department of Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY; §Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA; ‖Department of Medicine, Vanderbilt Ingram Cancer Center, Franklin, TN; and ¶Lowe center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479120PMC
March 2015

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.

Lancet Oncol 2014 Dec 5;15(13):1433-1441. Epub 2014 Nov 5.

State Key Laboratory in Oncology in South China, Hong Kong Cancer Institute, Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin NT, Hong Kong SAR, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)70461-9DOI Listing
December 2014

Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.

Clin Lung Cancer 2014 Nov 21;15(6):405-10. Epub 2014 Jun 21.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2014.06.002DOI Listing
November 2014

Emerging science and therapies in non-small-cell lung cancer: targeting the MET pathway.

Clin Lung Cancer 2014 Nov;15(6):475

Assistant Attending, Memorial Sloan-Kettering Cancer Center, Assistant Professor, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2014.08.001DOI Listing
November 2014

Clinical characteristics and course of 63 patients with BRAF mutant lung cancers.

J Thorac Oncol 2014 Nov;9(11):1669-74

Departments of *Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, †Epidemiology and Biostatistics, and ‡Pathology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000344DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251710PMC
November 2014

Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.

J Thorac Oncol 2014 Oct;9(10):e73-4

*Thoracic Oncology Service, Department of Medicine; †Computational Biology Center; ‡Thoracic Service, Department of Surgery; §Department of Pathology, Memorial Sloan-Kettering Cancer Center; and ‖Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153071
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000221DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655969PMC
October 2014

Comprehensive long-term care of patients with lung cancer: development of a novel thoracic survivorship program.

Ann Thorac Surg 2014 Sep 31;98(3):955-61. Epub 2014 Jul 31.

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2014.05.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713027PMC
September 2014

A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers.

J Thorac Oncol 2014 Sep;9(9):1272-7

*Memorial Sloan Kettering Cancer Center, New York, NY; †Tokyo Medical and Dental University, Tokyo, Japan; and ‡Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000256DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133740PMC
September 2014

Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.

Am J Surg Pathol 2014 Aug;38(8):1118-27

*Department of Surgery, Division of Thoracic Service §Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology Departments of †Pathology ∥Epidemiology and Biostatistics ¶Center for Cell Engineering, Memorial Sloan-Kettering Cancer Center, New York, NY ‡Faculty of Medicine, Department of Diagnostic Pathology, Kagawa University, Kagawa, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666292PMC
August 2014

Small-cell lung cancers in patients who never smoked cigarettes.

J Thorac Oncol 2014 Jun;9(6):892-6

*Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center; †Department of Medicine, Weill Cornell Medical College; ‡Department of Pathology; and §Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199745PMC
June 2014

Serpins promote cancer cell survival and vascular co-option in brain metastasis.

Cell 2014 Feb;156(5):1002-16

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Metastasis Research Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Howard Hughes Medical Institute, Chevy Chase, MD 21205, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2014.01.040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988473PMC
February 2014

Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

J Clin Oncol 2014 Jan 10;32(2):129-60. Epub 2013 Dec 10.

Jyoti D. Patel, Northwestern University; Blasé Polite, University of Chicago Medicine, Chicago, IL; Lada Krilov, American Society of Clinical Oncology, Alexandria, VA; Sylvia Adams and William L. Carroll, New York University Cancer Institute; Carol Aghajanian, Mark G. Kris, and Gary K. Schwartz, Memorial Sloan-Kettering Cancer Center, New York, NY; Ethan Basch, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Marcos de Lima and Mark R. Gilbert, University of Texas MD Anderson Cancer Center, Houston; Ian Thompson, University of Texas Health Science Center at San Antonio, San Antonio, TX; John L. Marshall, Lombardi Cancer Center, Washington, DC; Gregory A. Masters, Helen F. Graham Cancer Center, Newark, DE; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Sunil Sharma, Huntsman Cancer Institute, Salt Lake City, UT; Nicholas J. Vogelzang, US Oncology Research, Comprehensive Cancer Centers of Nevada, Henderson, NV; and Bruce J. Roth, Washington University in St Louis, St Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.7076DOI Listing
January 2014

Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers.

Cancer Chemother Pharmacol 2013 Oct 22;72(4):931-4. Epub 2013 Aug 22.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 300 E, 66th Street, New York, NY, 10065, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2263-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841970PMC
October 2013

Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab.

Cancer Chemother Pharmacol 2013 Aug 28;72(2):453-61. Epub 2013 Jun 28.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical School, 300 East 66th Street, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2219-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653739PMC
August 2013